United Therapeutics (UTHR) Tops Q4 EPS Views
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $500.17 -1.31%
Revenue Growth %: -1.2%
Financial Fact:
Total other (expense) income, net: 500K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Total other (expense) income, net: 500K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 adjusted EPS of $3.21, $1.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $346.4 million versus the consensus estimate of $336.22 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
- Rice Robotics Hong Kong signs non-binding cooperation deal with Vengine
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
